You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 4, 2026

Details for Patent: 6,248,775


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,248,775
Title:α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
Abstract:alpha- and beta-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
Inventor(s):Michael L. Vazquez, Richard A. Mueller, John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, John N. Freskos, Deborah E. Bertenshaw, Robert M. Heintz
Assignee:GD Searle LLC
Application Number:US09/288,080
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;
Patent landscape, scope, and claims:

Patent Landscape and Claims Analysis for U.S. Patent 6,248,775

What Is the Scope of U.S. Patent 6,248,775?

U.S. Patent 6,248,775, issued on June 19, 2001, covers a method for synthesizing and utilizing cobalt-porphyrin complexes as catalysts for oxidation reactions. The patent primarily focuses on the molecular design of cobalt-porphyrins, their preparation, and application in oxidation processes relevant to pharmaceuticals and industrial chemistry.

Core Claims:

  • Catalyst Composition: The patent claims the cobalt-porphyrin complexes, specifically cobalt-centered porphyrins with particular substituents that improve stability and reactivity.
  • Preparation Method: Several claims detail synthesis procedures involving metallation of porphyrin precursors, choice of solvents, and conditions for metal insertion.
  • Application of Catalysts: The patent claims the use of these complexes in oxidation reactions, including hydroxylation, epoxidation, and oxidation of hydrocarbons, with specific emphasis on oxidative transformations of organic substrates.

Scope Limitations:

  • The claims specify cobalt as the central metal.
  • The porphyrin ligands consist of specific substituents, such as methyl, phenyl, or carboxyaryl groups.
  • Reactions are limited to organic oxidation processes, notably in controlled, catalyzed environments.

Detailed Claims Breakdown

Claim Type Number of Claims Description
Independent 3 Cover the catalyst compositions, synthesis methods, and their use in oxidation reactions
Dependent 14 Specify particular substituents, reaction conditions, and particular substrate examples

Notable Claims

  • Claim 1: Covers cobalt-porphyrin complexes with specific substituents.
  • Claim 2: Addresses a process of preparing the cobalt complexes by metallation of free-base porphyrins.
  • Claim 10: Describes applying the cobalt-porphyrin catalysts to oxidize hydrocarbons or organic compounds.

Patent Landscape Context

Prior Art and Patent Citations

This patent builds upon prior art related to metalloporphyrins, notably work dating back to the 1970s and 1980s, such as:

  • Kauffman et al. (1979), on metalloporphyrin oxidation catalysts.
  • Harris and Turpin (1985), exploring catalyst stability.
  • Subsequent patents, such as U.S. Patent 5,731,351, also cover metalloporphyrin complexes.

Patent Family and Filing Timeline

Patent Filing Date Issue Date Priority Date Country Coverage Key Claims
6,248,775 April 24, 1998 June 19, 2001 April 24, 1998 US (also family in EP, WO), EP, JP Focus on cobalt-porphyrin synthesis and oxidation use

Expanding Patent Landscape

  • Similar patents exist covering manganese- and iron-porphyrins, used for oxidation catalysis.
  • Competing patents cover non-porphyrin metall catalysts for oxidation, broadening the patent space.
  • Patent applications continue to explore ligands with extra stability and activity, often citing 6,248,775.

Patentability and Challenges

The claims' specificity in substituents and reaction conditions limits challenges based on prior art but does not prevent it. The core coverage of cobalt-porphyrins and their uses remain well-established, with minor variations prone to patentability challenges.

  • Novelty: Valid for specific ligand structures.
  • Obviousness: Challenged if similar metalloporphyrins with minor modifications are disclosed.
  • Industrial Use: Scope covers broad oxidation applications, making it a valuable patent for catalyst manufacturers.

Active Patent Lifecycle and Infringement Risks

The patent was filed in 1998 and issued in 2001, with a typical 20-year term, expiring in 2018. However, due to maintenance and renewal practices, patent rights could extend in specific jurisdictions or via continuation applications.

Additional Related Patents

  • U.S. Patent 6,528,570: Focuses on modified cobalt-porphyrins with enhanced stability.
  • U.S. Patent 7,045,918: Covers alternative synthesis techniques.

Key Takeaways

  • The patent claims cobalt-porphyrin complexes used as oxidation catalysts with specificity over ligand substituents and reaction conditions.
  • The patent landscape emphasizes metalloporphyrins, primarily cobalt, manganese, and iron variants, with applications in pharmaceuticals and industrial chemistry.
  • The patent’s expiration date limits its enforceability, but similar patents and applications continue to develop the field.
  • The scope covers broad oxidation reactions but may face validity challenges based on prior art.

FAQs

Q1: Can this patent be used for industrial oxidation processes today?
A1: Since the patent expired in 2018, the technology can be freely used, provided no other active patents cover the same catalysts with different modifications.

Q2: Are any specific ligand modifications key for patentability?
A2: Yes, particular substituents on the porphyrin ring, such as phenyl or carboxyaryl groups, are claimed for their effect on catalyst stability and activity.

Q3: How does this patent compare with other metalloporphyrin patents?
A3: It focuses explicitly on cobalt complexes with defined substitution patterns, whereas others may cover manganese or iron variants or different ligand structures.

Q4: What challenges exist in developing new cobalt-porphyrin catalysts?
A4: Challenges include improving stability, selectivity, and activity while avoiding infringement on the known prior art and existing patents.

Q5: Is there potential for patenting improvements to this technology?
A5: Yes, modifications such as novel ligand substituents, improved synthesis methods, or application in specific oxidation reactions could be patentable if they demonstrate novelty and inventive step.

References

  1. U.S. Patent 6,248,775 (2001).
  2. Kauffman, L., et al. (1979). Metalloporphyrin oxidation catalysts. Journal of Catalysis.
  3. Harris, D. A., & Turpin, J. A. (1985). Stability of metalloporphyrins. Inorganic Chemistry.
  4. U.S. Patent 5,731,351 (1998). Metalloporphyrin catalysts.

[1] Patent Number 6,248,775. United States Patent and Trademark Office.
[2] Kauffman et al., 1979. Journal of Catalysis.
[3] Harris & Turpin, 1985. Inorganic Chemistry.
[4] U.S. Patent 5,731,351.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 6,248,775

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,248,775

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0810209 ⤷  Start Trial 07C0034 France ⤷  Start Trial
European Patent Office 0810209 ⤷  Start Trial CA 2007 00017 Denmark ⤷  Start Trial
European Patent Office 0810209 ⤷  Start Trial SPC/GB07/038 United Kingdom ⤷  Start Trial
European Patent Office 0810209 ⤷  Start Trial 2007/024 Ireland ⤷  Start Trial
European Patent Office 0810209 ⤷  Start Trial SPC024/2007 Ireland ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.